LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | PI103 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 1617 | 4513 | 0.3583 | 0.1164 |
MDA-MB-231 | PLX-4720 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4537 | 4513 | 1.0053 | 1.0073 |
MDA-MB-231 | QL-X-138 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 3389 | 4513 | 0.7510 | 0.6571 |
MDA-MB-231 | QL-XII-47 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 1785 | 4513 | 0.3955 | 0.1676 |
MDA-MB-231 | Radicicol | 0.37 | uM | LJP5 | 72 | hr | 1235 | 1705 | 4513 | 0.3778 | 0.1432 |
MDA-MB-231 | Radicicol | 0.37 | uM | LJP6 | 72 | hr | 1235 | 1539 | 4513 | 0.3410 | 0.0925 |
MDA-MB-231 | Seliciclib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4369 | 4513 | 0.9680 | 0.9559 |
MDA-MB-231 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4096 | 4513 | 0.9075 | 0.8726 |
MDA-MB-231 | XL147 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4822 | 4513 | 1.0683 | 1.0941 |
MDA-MB-231 | Saracatinib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 2933 | 4513 | 0.6500 | 0.5180 |
MDA-MB-231 | Selumetinib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 3086 | 4513 | 0.6837 | 0.5644 |
MDA-MB-231 | Sirolimus | 0.37 | uM | LJP6 | 72 | hr | 1235 | 3473 | 4513 | 0.7695 | 0.6825 |
MDA-MB-231 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 4437 | 4513 | 0.9830 | 0.9766 |
MDA-MB-231 | SU11274 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4429 | 4513 | 0.9813 | 0.9742 |
MDA-MB-231 | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 3655 | 4513 | 0.8099 | 0.7382 |
MDA-MB-231 | TGX221 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4099 | 4513 | 0.9082 | 0.8736 |
MDA-MB-231 | Torin1 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 1650 | 4513 | 0.3657 | 0.1265 |
MDA-MB-231 | Torin2 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 1087 | 4513 | 0.2408 | -0.0454 |
MDA-MB-231 | Tozasertib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 1444 | 4513 | 0.3199 | 0.0635 |
MDA-MB-231 | Trametinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 1329 | 4513 | 0.2945 | 0.0285 |
MDA-MB-231 | TWS119 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4018 | 4513 | 0.8903 | 0.8489 |
MDA-MB-231 | Vemurafenib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4614 | 4513 | 1.0222 | 1.0306 |
MDA-MB-231 | Withaferin A | 0.37 | uM | LJP5 | 72 | hr | 1235 | 2841 | 4513 | 0.6294 | 0.4897 |
MDA-MB-231 | Withaferin A | 0.37 | uM | LJP6 | 72 | hr | 1235 | 2493 | 4513 | 0.5525 | 0.3837 |
MDA-MB-231 | WYE-125132 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 1597 | 4513 | 0.3539 | 0.1103 |